| Subject: | FDA Issues Notice about Misbranding of Ziagen as Combivir |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Mon, 16 Apr 2007 - 12:00 am |
| Audience: Pharmacists, other healthcare professionals
The FDA and GlaxoSmithKline have informed healthcare professionals of an apparent third-party tampering that resulted in the misbranding of Ziagen as Combivir and employed counterfeit labels for Combivir Tablets. Both medications are used as part of combination regimens to treat HIV+ infection. Two 60-count misbranded bottles of Combivir Tablets contained 300 mg tablets of Ziagen.
The counterfeit labels identified are Lot No. 6ZP9760 with... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! provides immediate online healthcare compliance validation to our healthcare users. When faced with dramatic reductions in healthcare dollars, StayAlert! focuses on those processes that can save the most time and money. By automating labor-intensive activities, StayAlert! almost instantly produces a positive impact on the healthcare user's bottom line. The policies alone included with the StayAlert! notices can save you $65,000 or more in labor costs each year. Organizations will realize dramatic cost savings through elimination of labor intensity, increased productivity with the benefit of ensuring regulatory compliance. StayAlert! is the service-oriented supplier of health care's compliance needs. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
